Predicting factors for recurrence in low-grade Ta primary bladder tumours

Area of Science:

• Urology
• Oncology
• Pathology

Background:

• Ta bladder tumors are the most common primary bladder neoplasms, with a high recurrence rate.
• Low-grade (G1) Ta tumors have a 15-38% chance of recurrence within the first year.
• Identifying predictors of recurrence is crucial for effective patient management.

Purpose of the Study:

• To identify predictive factors for the first recurrence of TaG1 primary bladder tumors.
• To analyze the impact of various patient and tumor characteristics on recurrence risk.
• To evaluate the role of adjuvant therapy in preventing recurrence.

Main Methods:

• Retrospective analysis of 68 patients diagnosed with TaG1 bladder tumors between 2004 and 2012.
• Tumor staging and grading according to WHO classification and TNM staging.
• Comparison of recurrence rates between patients who received adjuvant Mitomycin C and those who did not.
• Kaplan-Meier survival analysis and log-rank test for statistical evaluation.

Main Results:

• 35.3% of patients experienced tumor recurrence.
• The absence of adjuvant Mitomycin C treatment was the sole factor significantly associated with recurrence (p<0.001).
• Patients not receiving adjuvant therapy had a 17.5-fold increased risk of recurrence (95% CI: 7.6-30.2).

Conclusions:

• Adjuvant Mitomycin C therapy is a critical factor in preventing TaG1 bladder tumor recurrence.
• The protective effect of adjuvant therapy is independent of patient demographics and tumor characteristics.
• Implementing adjuvant therapy can significantly reduce the risk of tumor relapse.